SK 10
Alternative Names: SK-10Latest Information Update: 10 Jul 2024
At a glance
- Originator Zhiyi Biotechnology
- Class Anti-inflammatories; Antidiarrhoeals; Bacteria
- Mechanism of Action Bacteria replacements; Cytokine inhibitors; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diarrhoea
Most Recent Events
- 05 Jul 2024 Adverse events data from a phase I trial in Diarrhoea released by Guangzhou Zhiyi Biotechnology
- 05 Jul 2024 Guangzhou Zhiyi Biotechnology completes the phase I trial in Diarrhoea in USA (PO) (NCT06026397)
- 21 Nov 2022 Phase-I clinical trials in Diarrhoea in USA (PO), prior to November 2022 (Zhiyi Biotechnology pipeline, November 2022)